This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 686 trials Clear all
Filter by:

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma

  • Status Recruiting
    Recruiting
  • Condition Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblas...
    Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblas...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Device: Sonication for opening of blood-brain barrier, Drug: Chemotherapy, albumin-bound paclitaxel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Device: Sonication for opening of blood-brain barrier, Drug: Chemotherapy, albumin-bound paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Northwestern Memorial Hospital, Chicago, Illinois, United States

Brief Summary

Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to temporarily and reversibly open the BBB immediately prior to chemotherapy infusion with albumin-bound paclitaxel. In this phase 1 trial increasing doses of chemotherapy will be delivered as long deemed safe and prior patient had not experienced severe toxicity. Once the the recommended dosing has been established, additional patients will be treated in order to better evaluate the antitumor efficacy of this novel treatment. The device will be implanted at the time of surgical resection of the recurrent tumor. During that procedure a first test dose of the chemotherapy will be administered in the operating room after sonication (procedure of activating ultrasound and opening the BBB) and tissue concentrations in different parts of the resected tumor will be measured. In select patients, the sonication procedure will occur immediately after the test dose of chemotherapy is administered. The objectives of this trial are to establish a safe and effective dose of ABX, to demonstrate that the opening of the BBB increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

  • Status Recruiting
    Recruiting
  • Condition Early Stage Non-small Cell Lung Cancer
    Early Stage Non-small Cell Lung Cancer
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Biological: Camrelizumab, Drug: Pemetrexed, Drug: Nab-paclitaxel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Biological: Camrelizumab, Drug: Pemetrexed, Drug: Nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Brief Summary

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Esophageal Cancer
    Esophageal Cancer
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: placebo, Drug: cisplatin, Drug: anti-PD-L1 antibody, Drug: albumin bound paclitaxel, Procedure: radical resection of esophageal carcinoma

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: placebo, Drug: cisplatin, Drug: anti-PD-L1 antibody, Drug: albumin bound paclitaxel, Procedure: radical resection of esophageal carcinoma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Brief Summary

This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in perioperative chemotherapy of esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The immunotherapy will be given before and after the operation every three weeks.

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

  • Status Recruiting
    Recruiting
  • Condition Lung Cancer, Non-small Cell, Artificial Intelligence
    Lung Cancer, Non-small Cell, Artificial Intelligence
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Camrelizumab + Nab-paclitaxel + Carboplatin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Camrelizumab + Nab-paclitaxel + Carboplatin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Brief Summary

This prospective, single-arm, multicenter, phase II trial enrolled 40 patients who underwent surgery after three cycles of neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin. The MPR is the primary endpoint, and the pCR, the complete resection rate, the objective response rate, the disease-free survival, adverse events, and quality of life are the secondary endpoints. The exploratory endpoints will be used to establish a multiomics artificial intelligence system for neoadjuvant therapy effect prediction and decision-making assistance based on radiomics, metabolism, genetic, and clinic-pathological characteristics and to explore drug resistance mechanisms.

Saltikva for Metastatic Pancreatic Cancer

  • Status Recruiting
    Recruiting
  • Condition Metastatic Pancreatic Cancer
    Metastatic Pancreatic Cancer
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Salmonella-IL2, Drug: FOLFIRINOX Alone (Historical Controls), Drug: Gemcitabine/Abraxane Alone (Historical Controls)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Salmonella-IL2, Drug: FOLFIRINOX Alone (Historical Controls), Drug: Gemcitabine/Abraxane Alone (Historical Controls)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Segal Cancer Centre/ Mortimer B. Davis-Jewish General Hosptial, Montreal, Quebec, Canada

Brief Summary

Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and Saltikva). Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV metastatic pancreatic cancer will significantly prolong the overall survival and prolong the time to disease progression. Patient Population: unresectable, metastatic pancreatic cancer patients 18 years of age or older

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

  • Status Recruiting
    Recruiting
  • Condition Pancreatic Cancer, Chemotherapy Effect
    Pancreatic Cancer, Chemotherapy Effect
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Gemcitabine, Drug: Nab-paclitaxel, Drug: Pembrolizumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: Irinotecan, Drug: 5FU

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Gemcitabine, Drug: Nab-paclitaxel, Drug: Pembrolizumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: Irinotecan, Drug: 5FU

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Seoul National University Hospital, Seoul, Korea, Republic of

Brief Summary

This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Non-small Cell Lung Carcinoma
    Non-small Cell Lung Carcinoma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Drug: Pemetrexed, Biological: Ipilimumab, Drug: Erlotinib, Drug: Gefitinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Carboplatin, Biological: Bevacizumab, Drug: Pemetrexed, Biological: Ipilimumab, Drug: Erlotinib, Drug: Gefitinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung cancer (NSCLC).

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

  • Status Recruiting
    Recruiting
  • Condition Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer A...
    Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer A...
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Bosentan, Drug: Gemcitabine, Drug: Nab-paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Bosentan, Drug: Gemcitabine, Drug: Nab-paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope Medical Center, Duarte, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of bosentan and how well it works when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic cancer that cannot be removed by surgery (unresectable). Bosentan may block the hormone endothelin and prevent the growth and spread of pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bosentan with chemotherapy (gemcitabine and nab-paclitaxel) may work better in treating patients with pancreatic cancer compared to chemotherapy alone.

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

  • Status Recruiting
    Recruiting
  • Condition Breast Cancer, Renal Cell Carcinoma
    Breast Cancer, Renal Cell Carcinoma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: IPI-549 (eganelisib), Drug: Atezolizumab, Drug: nab-paclitaxel, Drug: Bevacizumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: IPI-549 (eganelisib), Drug: Atezolizumab, Drug: nab-paclitaxel, Drug: Bevacizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ironwood Cancer and Research Center, Chandler, Arizona, United States

Brief Summary

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

  • Status Recruiting
    Recruiting
  • Condition Nasopharyngeal Carcinoma
    Nasopharyngeal Carcinoma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Nab-paclitaxel

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

No. 156, North Road, Xierhuan Road, Fuzhou, Fujian, China

Brief Summary

Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in most parts of the world. According to the World Health Organization survey, 80% of nasopharyngeal carcinomas occur in China, with high incidence in southern China, as high as 30-50/100,000, such as Guangdong, Guangxi, Hunan, and Fujian. In 2015, Chinese cancer statistics showed that there were about 60,600 new cases of nasopharyngeal carcinoma in China, and the number of deaths was about 34,100. Radiation therapy is the main treatment for nasopharyngeal carcinoma. Early stage I and IIa achieved a 5-year survival rate (OS) of 90% and 84%, respectively . However, the treatment outcomes of most patients with locally advanced nasopharyngeal carcinoma are not ideal.